Enthusiastic analyst comment drives BioSphere price up 40%
This article was originally published in Clinica
BioSphere Medical shares rose 40% last week following a favourable comment from a Salomon Smith Barney analyst as he initiated coverage of the development-stage company. The shares rose nearly $5 to finish last Monday on just over $16.50. The analyst, Phil Nailbone, said that the expected target for the company's shares in a year was around $26.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.